Ann Allergy Asthma Immunol. 2022 Aug;129(2):169-180. doi: 10.1016/j.anai.2022.02.021. Epub 2022 Mar 7.
PMID:35272048
Severe eosinophilic asthma in Chinese C-BIOPRED asthma cohort.
Zhang Q, Fu X, Wang C, Shen H, Zhu L, Shi G, Qiu Z, Wen Z, Gu W, Luo W, Zhao L, Chen Y, Lim S, Xiao C, Kang J, Zhang Y, Huang M, Xu J, Huang K, Li Q, Zhang X, Zhao J, Liu X, Sun S, Tang H, He B, Cai S, Chen P, Wei C, Wang G, Chen P, Xie L, Lin J, Tang Y, Han Z, Chung KF, Zhong N; C-BIOPRED consortium.
Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study.
Jackson DJ, Heaney LG, Humbert M, Kent BD, Shavit A, Hiljemark L, Olinger L, Cohen D, Menzies-Gow A, Korn S; SHAMAL Investigators.
Lancet. 2024 Jan 20;403(10423):271-281. doi: 10.1016/S0140-6736(23)02284-5. Epub 2023 Dec 7.
PMID:38071986
Pulmonary eosinophilia.
CROFTON JW, LIVINGSTONE JL, OSWALD NC, ROBERTS AT.